经皮冠状动脉介入治疗术后患者CYP2C19基因多态性与血浆ABCC3水平的相关性研究
摘要
目的评价经皮冠状动脉介入治疗(PCI)术后患者CYP2C19基因多态性与血浆ABCC3水平的相关性。方法选取PCI术后患者149例,根据其CYP2C19基因型分为快代谢型(CYP2C19*1/*1)、中等代谢型(CYP2C19*1/*2、CYP2C19*1/*3)和慢代谢型(CYP2C19*2/*2、CYP2C19*2/*3、CYP2C19*3/*3)3组,比较3组ABCC3水平。结果快代谢组53例(35.57%);中代谢组75例(50.34%);慢代谢组21例(14.09%)。快代谢型、中等代谢型和慢代谢型3组之间ABCC3水平差异无统计学意义(P>0.05)。结论 PCI术后患者CYP2C19基因多态性与血浆ABCC3水平无显著相关性,但ABCC3水平在快代谢型、中等代谢型和慢代谢型3组中呈下降趋势。
引文
[1] 中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中华心血管病杂志,2012,40(4):271-277.
[2] 杨跃进.心血管急症救治(12)经皮冠状动脉介入治疗的风险防范(续完)[J].中国循环杂志.2014,29(10):764-766.
[3] 2012 Writing Committee Members,Jneid H,Anderson JL,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina /mon-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the american college of cardiology foundation/american heart association task force on practice guidelines[J].Circulation,2012,126(7):875-910.
[4] 唐千捷,钟诗龙,林浩铭,等.MicroRNAs表达与药物代谢酶CYP2C19活性相关性研究[J].广东药学院学报,2016,32(2):243-247.
[5] 夏金喜,肖建民,万德立,等.急性冠脉综合征PCI术后患者CYP2C19*2、 CYP2C19*3基因多态性与氯吡格雷抵抗及临床预后的关系[J].中国心血管病研究,2015,13(8):731-734.
[6] M■rginean A,B■nescu C,Moldovan V,et a1.The Impact of CYP2C19 Loss-of-Function Polymorphisms,Clinical,and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry[J].Clin Appl Thromb Hemost,2016:12.
[7] 简斌,赵继先,张涛,等.CYP2C19基因多态性检测指导治疗反复支架内血栓形成一例[J].中华内科杂志,2015,54(2):147-149.
[8] Jian Liu,Xiao-Yan Nie,Yong Zhan,et a1.CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome[J].Chinese Medical Journal,2015,128(16):2183-2188.
[9] Yang J,Zhou JS,Zhang YD,et a1.The association of ABCC3 promoter methylation with clopidogrel response in Chinese ischemic stroke patients[J].Pharmazie,2014,69(10):764-768.
[10] Zou JJ,Fan HW,Chen SL,et a1.Efffect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention[J].Clin Exp Pharmacol Physiol,2013,40(8):504-509.
[2] 杨跃进.心血管急症救治(12)经皮冠状动脉介入治疗的风险防范(续完)[J].中国循环杂志.2014,29(10):764-766.
[3] 2012 Writing Committee Members,Jneid H,Anderson JL,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina /mon-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the american college of cardiology foundation/american heart association task force on practice guidelines[J].Circulation,2012,126(7):875-910.
[4] 唐千捷,钟诗龙,林浩铭,等.MicroRNAs表达与药物代谢酶CYP2C19活性相关性研究[J].广东药学院学报,2016,32(2):243-247.
[5] 夏金喜,肖建民,万德立,等.急性冠脉综合征PCI术后患者CYP2C19*2、 CYP2C19*3基因多态性与氯吡格雷抵抗及临床预后的关系[J].中国心血管病研究,2015,13(8):731-734.
[6] M■rginean A,B■nescu C,Moldovan V,et a1.The Impact of CYP2C19 Loss-of-Function Polymorphisms,Clinical,and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry[J].Clin Appl Thromb Hemost,2016:12.
[7] 简斌,赵继先,张涛,等.CYP2C19基因多态性检测指导治疗反复支架内血栓形成一例[J].中华内科杂志,2015,54(2):147-149.
[8] Jian Liu,Xiao-Yan Nie,Yong Zhan,et a1.CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome[J].Chinese Medical Journal,2015,128(16):2183-2188.
[9] Yang J,Zhou JS,Zhang YD,et a1.The association of ABCC3 promoter methylation with clopidogrel response in Chinese ischemic stroke patients[J].Pharmazie,2014,69(10):764-768.
[10] Zou JJ,Fan HW,Chen SL,et a1.Efffect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention[J].Clin Exp Pharmacol Physiol,2013,40(8):504-509.